Fmr LLC Has $3.07 Million Holdings in Artivion, Inc. (NYSE:AORT)

Fmr LLC increased its stake in shares of Artivion, Inc. (NYSE:AORTFree Report) by 28.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 115,184 shares of the company’s stock after acquiring an additional 25,176 shares during the period. Fmr LLC owned 0.27% of Artivion worth $3,066,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AORT. nVerses Capital LLC acquired a new stake in shares of Artivion in the second quarter worth $28,000. RiverPark Advisors LLC acquired a new position in shares of Artivion in the second quarter valued at $55,000. RW Investment Management LLC bought a new position in Artivion in the second quarter worth $219,000. Intech Investment Management LLC bought a new stake in Artivion in the 2nd quarter valued at $253,000. Finally, XTX Topco Ltd bought a new position in shares of Artivion during the 2nd quarter worth about $331,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Artivion

In other news, SVP Jean F. Holloway sold 8,070 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $30.12, for a total transaction of $243,068.40. Following the completion of the sale, the senior vice president now directly owns 153,862 shares of the company’s stock, valued at $4,634,323.44. The trade was a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Amy Horton sold 4,329 shares of the firm’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $29.66, for a total transaction of $128,398.14. Following the transaction, the chief accounting officer now directly owns 135,660 shares in the company, valued at $4,023,675.60. The trade was a 3.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,447 shares of company stock worth $925,424. Insiders own 8.10% of the company’s stock.

Artivion Stock Down 1.9 %

NYSE AORT opened at $28.93 on Friday. Artivion, Inc. has a fifty-two week low of $16.48 and a fifty-two week high of $30.45. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The business has a fifty day moving average price of $27.70 and a two-hundred day moving average price of $26.22. The stock has a market capitalization of $1.21 billion, a PE ratio of -1,446.50 and a beta of 1.75.

Analyst Ratings Changes

AORT has been the topic of several recent analyst reports. Oppenheimer boosted their price target on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. JMP Securities reissued a “market outperform” rating and set a $33.00 price target on shares of Artivion in a research note on Tuesday, December 10th. Stifel Nicolaus lifted their price objective on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, September 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $34.00 price objective on shares of Artivion in a report on Monday, December 9th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $31.80.

View Our Latest Report on Artivion

Artivion Profile

(Free Report)

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

Featured Stories

Want to see what other hedge funds are holding AORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Artivion, Inc. (NYSE:AORTFree Report).

Institutional Ownership by Quarter for Artivion (NYSE:AORT)

Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.